Northern Trust’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-568,557
| Closed | -$102M | – | 4328 |
|
|
2017
Q3 | $102M | Sell |
568,557
-22,582
| -4% | -$3.15M | 0.03% | 541 |
|
|
2017
Q2 | $61.3M | Buy |
591,139
+100,477
| +20% | +$8.2M | 0.02% | 777 |
|
|
2017
Q1 | $38.5M | Buy |
490,662
+40,370
| +9% | +$2.5M | 0.01% | 1127 |
|
|
2016
Q4 | $20.2M | Buy |
450,292
+4,665
| +1% | +$229K | 0.01% | 1613 |
|
|
2016
Q3 | $24.9M | Buy |
445,627
+89
| +0% | +$4.96K | 0.01% | 1410 |
|
|
2016
Q2 | $22.3M | Buy |
445,538
+69,248
| +18% | +$3.4M | 0.01% | 1442 |
|
|
2016
Q1 | $17.3M | Buy |
376,290
+41,334
| +12% | +$2M | 0.01% | 1593 |
|
|
2015
Q4 | $20.6M | Buy |
334,956
+16,524
| +5% | +$1.16M | 0.01% | 1487 |
|
|
2015
Q3 | $17.7M | Buy |
318,432
+188,138
| +144% | +$11.8M | 0.01% | 1578 |
|
|
2015
Q2 | $7.94M | Buy |
130,294
+15,474
| +13% | +$883K | ﹤0.01% | 2213 |
|
|
2015
Q1 | $6.62M | Buy |
114,820
+12,306
| +12% | +$825K | ﹤0.01% | 2332 |
|
|
2014
Q4 | $5.91M | Buy |
102,514
+79,607
| +348% | +$3.35M | ﹤0.01% | 2396 |
|
|
2014
Q3 | $652K | Buy |
+22,907
| New | +$567K | ﹤0.01% | 3512 |
|
Northern Trust's KITE Position: Q4 2017 in Review
Northern Trust sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 568,557 shares — an estimated $102M sold.
Northern Trust first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $102M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Northern Trust reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Northern Trust sold 568,557 Kite Pharma, Inc. shares in Q4 2017, an estimated $102M.
- Northern Trust first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
- Northern Trust's Kite Pharma, Inc. position peaked at $102M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Northern Trust's 13F filing for Q4 2017, filed 14 Feb 2018.